Accessibility Menu
Cannara Biotech logo

Cannara Biotech(TSXV) LOVE

Current PriceN/A
Market CapN/AMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Since IPO (2019)-39%
5 Year+9%
1 Year+4%
1 Month+16%
Cannara Biotech last closing stock price
MetricPriceDate
Last closeCAD 1.862026-07-23
Cannara Biotech stock price return by period
PeriodPrice returnPrice at period startPeriod start date
1 week-3.12%CAD 1.922026-07-16
1 month+16.25%CAD 1.602026-06-23
3 month+2.2%CAD 1.822026-04-24
Year to date+6.9%CAD 1.742025-12-31
1 year+4.49%CAD 1.782025-07-23
3 year+102.17%CAD 0.922023-07-24
5 year+9.41%CAD 1.702021-07-23
Since inception-39.02%CAD 3.052019-01-14

Cannara Biotech Financials at a Glance

Market Cap

N/AMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Revenue (TTM)

CA$113.26M

Net Income (TTM)

CA$10.16M

EPS (TTM)

N/A

P/E Ratio

N/A

Dividend

N/A

Beta (Volatility)

N/A

Price

N/A

Volume

N/A

Open

N/A

Previous Close

N/A

Daily Range

N/A

52-Week Range

N/A

Estimated Earnings Date

Apr 27, 2026

LOVE News

No articles available.

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Cannara Biotech

Cannara Biotech Inc. specializes in the indoor cultivation, processing, and commercialization of cannabis and its derivative products across Canada. Established in 2017, the company also supplies hemp-derived CBD items through its online retail platform, positioning itself as a key player in the growing cannabis industry.

Products and Services
  • Indoor cultivation of cannabis and derivative products
  • Processing and commercialization of cannabis products
  • Online retail platform for hemp-derived CBD items
Growth Outlook
  • Revenue of CAD 27.2 million in the latest quarter, showing strong demand
  • Gross profit margin improved to 43% in Q2 2026
  • Significant cash flow from operations of CAD 2.9 million in Q2 2026
Financial Highlights
  • Net income of CAD 1.7 million in Q2 2026, reflecting profitability
  • Current ratio of 2.7 indicates strong liquidity position
  • Trailing twelve months (TTM) P/E ratio of 13.8 suggests attractive valuation
Cannara Biotech Inc. has demonstrated robust financial performance, particularly in the latest quarter, with a revenue of CAD 27.2 million and a net income of CAD 1.7 million. The company’s gross profit margin has shown improvement, reaching 43% in Q2 2026, indicating effective cost management and operational efficiency. The current ratio of 2.7 highlights a strong liquidity position, allowing for flexibility in meeting short-term obligations. Additionally, the TTM P/E ratio of 13.8 suggests that the stock may be attractively valued compared to industry peers. Overall, Cannara Biotech Inc. is well-positioned to capitalize on the growing demand for cannabis products in Canada.
AI Generated • Jul 1, 2026

Industry

Personal Products

Sector

Consumer Staples

Employees

452

CEO

Zohar Krivorot

Website

www.cannara.ca

Headquarters

Saint-Laurent, QC H4N 3M9, CA

LOVE Financials

Key Financial Metrics (TTM)

Gross Margin

26.30%

Operating Margin

0.10%

Net Income Margin

9.22%

Return on Equity

9.45%

Return on Capital

15.44%

Return on Assets

5.58%

Earnings Yield

N/A

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

N/AMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Shares Outstanding

N/A

Volume

N/A

Avg. Volume

N/A

Financials (TTM)

Gross Profit

CA$43.18M

Operating Income

CA$13.38M

EBITDA

CA$24.34M

Operating Cash Flow

CA$27.11M

Capital Expenditure

-CA$11.53M

Free Cash Flow

CA$15.58M

Cash & ST Invst.

CA$21.90M

Total Debt

CA$34.22M

Cannara Biotech Performance Analysis

Cannara Biotech annual revenue and year-over-year revenue growth by fiscal year
Fiscal yearPeriod endRevenueYoY growth
20222022-08-31CAD 35,841,386110.6%
20232023-08-31CAD 57,260,19359.8%
20242024-08-31CAD 81,747,55142.8%
20252025-08-31CAD 107,202,53531.1%
Cannara Biotech sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q32025-05-312.8%
Q42025-08-314.8%
Q12025-11-305.2%
Q22026-02-28-9.7%
Cannara Biotech annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal yearPeriod endDiluted EPSYoY growth
20222022-08-31CAD 0.03N/A
20232023-08-31CAD 0.08196.9%
20242024-08-31CAD 0.07-9.5%
20252025-08-31CAD 0.14101.1%
Cannara Biotech sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q32025-05-3124.5%
Q42025-08-31-19.0%
Q12025-11-30-70.2%
Q22026-02-2885.2%

Revenue Growth Rate

Annual and quarterly growth comparison

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q2 2026YOY CHG

Revenue

CA$27.18M

+2.2%

Gross Profit

CA$11.65M

-2.6%

Gross Margin

42.86%

N/A

Market Cap

N/AMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

N/A

Market Cap/Employee

N/A

N/A

Employees

461

N/A

Net Income

CA$1.66M

-49.8%

EBITDA

CA$4.63M

-36.9%

Quarterly Fundamentals

Name
Q2 2026YOY CHG

Total Cash

CA$21.90M

+333.3%

Total Debt

CA$34.22M

-30.0%

Accounts Receivable

CA$12.47M

-19.9%

Inventory

CA$54.15M

+19.2%

Long Term Debt

CA$25.22M

-26.0%

Short Term Debt

CA$9.00M

-39.1%

Return on Assets

5.58%

N/A

Return on Invested Capital

0.07%

N/A

Free Cash Flow

-CA$286.30K

+94.1%

Operating Cash Flow

CA$2.95M

+187.1%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
HLS.TOHLS Therapeutics Inc.
CA$4.11-2.38%
RX.VBioSyent Inc.
CA$14.69+1.03%
CRDL.TOCardiol Therapeutics Inc.
CA$1.74-4.40%
XLY.TOAuxly Cannabis Group Inc.
CA$0.18-2.70%

Trending Stocks

Symbol / CompanyPricePrice Chg
TSLLDirexion Shares ETF Trust - Direxion Daily Tsla Bull 2x Shares
$7.76-0.29%
INTCIntel
$100.23-0.02%
AALAmerican Airlines Group
$13.56-0.08%
TAT&T
$22.96-0.00%

Questions About LOVE

What is the current price of Cannara Biotech?

Cannara Biotech is trading at N/A per share.

What is the 52-week range for Cannara Biotech?

Over the past 52 weeks, Cannara Biotech has traded between N/A and N/A.

How much debt does Cannara Biotech have?

As of the most recent reporting period, Cannara Biotech reported total debt of CA$37.00M.

How much cash does Cannara Biotech have on hand?

Cannara Biotech reported CA$21.81M in cash and cash equivalents in its most recent financial results.

What is Cannara Biotech’s dividend yield?

Cannara Biotech does not currently have a dividend yield.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.

View Premium Services